. .. Traitements,

, 61 6.1.5. Inhibiteurs de la dopa-décarboxylase périphérique (IDDP)

, PARTIE 2 : L'apport de l'imagerie moléculaire appliquée à la thérapie de la maladie de Parkinson, p.69

. .. Maldi-tof, Exposition de résultats d'analyses préliminaires réalisées par MALDI, vol.26

, 79 8.1. Analyse de coupes cérébrales murines témoin et test, Analyse quantitative comparative de phospholipides sur des coupes encéphaliques murines

, Application de l'imagerie moléculaire à la maladie de Parkinson

J. Parkinson, Member of the Royal College of Surgeons. An Essay on the Shaking Palsy

I. Benatru and C. Fayard, Place de la L-dopa dans la maladie de Parkinson en, La Lettre du Neurologue, vol.15, p.2, 2011.

O. Hornykiewicz, G. Hitzenberger, and H. Zellner, Experimental-pharmacological and clinical studies on a new spasmolytic "Spadon, Wien Klin Wochenschr, vol.75, pp.189-92, 1963.

G. C. Cotzias, P. S. Pappavasiliou, and R. Gellene, Modification of parkinsonism-chronic treatment with L-DOPA, The New England Journal of Medicine, vol.280, pp.337-382, 1969.

M. G. Spillantini, M. L. Schmidt, V. Lee, J. Q. Trojanowski, and R. Jakes, ?-Synuclein in Lewy bodies, Nature, vol.388, pp.839-840, 1997.

A. Ulusoy, D. Monte, and D. A. , 2013) ?-synuclein elevation in human neurodegenerative diseases: Experimental, pathogenetic, and therapeutic implications, Mol. Neurobiol, vol.47, pp.484-494

M. G. Spillantini and G. M. , The ?-Synucleinopathies : Parkinson's, 2000.

. Disease, Dementia with Lewy Bodies, and Multiple System Atrophy, Ann. N.Y. Acad. Sci, vol.920, pp.16-27

R. Pariary, D. Bhattacharyya, and A. Bhunia, Mitochondrial-membrane association of ?synuclein: Pros and cons in consequence of Parkinson's disease pathophysiology, Gene Reports, vol.16, p.100423, 2019.

. Mg-spillantini, . Schmidt, . Vm-lee, . Trojanowski, M. Jakes et al., ?-synuclein in Lewy bodies, Nature, vol.388, pp.839-840, 1997.

R. Pariary, D. Bhattacharyya, and A. Bhunia, Mitochondrial-membrane association of ?-synuclein: Pros and cons in consequence of Parkinson's disease pathophysiology, Gene Reports, vol.16, p.100423, 2019.

F. Theillet, A. Binolfi, B. Bekei, A. Martorana, H. M. Rose et al., Marleen van Rossum, Daniella Goldfarb & Philipp Selenko. Structural disorder of monomeric ?-synuclein persists in mammalian cells, Nature, vol.530, pp.45-50, 2016.

M. M. Moosa, J. C. Ferreon, and A. C. Ferreon, Single-molecule FRET detection of early-stage conformations in ?-synuclein aggregation, Methods in Molecular Biology, pp.221-233, 1948.

D. Bhattacharyya, R. Kumar, S. Mehra, A. Ghosh, S. K. Maji et al., Multitude NMR studies of ?-synuclein familial mutants: probing their differential aggregation propensities, Chem Commun (Camb), vol.54, issue.29, pp.3605-3608, 2018.

C. Eichmann and S. Campioni, Preparation and Characterization of Stable ?-Synuclein Lipoprotein Particles

, J Biol Chem, vol.291, issue.16, pp.8516-8543, 2016.

A. Abeliovich, Y. Schmitz, I. Fariñas, D. Choi-lundberg, W. H. Ho et al., Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system, Neuron, vol.25, issue.1, pp.239-52, 2000.

V. M. Nemani, W. Lu, V. Berge, K. Nakamura, B. Onoa et al., Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis, Neuron, vol.65, issue.1, pp.66-79, 2010.

J. Burre, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton et al., ?-synuclein promotes snare-complex assembly in vivo and in vitro, Science, vol.329, pp.1663-1667, 2010.

H. J. Lee, S. J. Kang, K. Lee, and H. Im, Human ?-synuclein modulates vesicle trafficking through its interaction with prenylated rab acceptor protein 1, Biochem. Biophys. Res. Commun, vol.412, pp.526-531, 2011.

V. M. Nemani, W. Lu, V. Berge, K. Nakamura, B. Onoa et al., Increased expression of ?-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis, Neuron, vol.65, pp.66-79, 2010.

M. Ramezani, M. M. Wilkes, T. Das, D. Holowka, D. Eliezer et al., Regulation of exocytosis and mitochondrial relocalization by Alpha-synuclein in a mammalian cell model, Npj Parkinson's Disease, vol.5, p.12, 2019.

J. H. Soper, S. Roy, A. Stieber, E. Lee, R. B. Wilson et al., Alphasynuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae, Mol Biol Cell, vol.19, issue.3, pp.1093-103, 2008.

J. Diao, J. Burré, S. Vivona, D. J. Cipriano, M. Sharma et al., Native ?-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife, vol.2, p.592, 2013.

W. S. Davidson, J. A. Clayton, D. F. George, and J. M. , Stabilization of alphasynuclein secondary structure upon binding to synthetic membranes, J Biol Chem

, Apr, vol.17, issue.16, pp.9443-9452

J. E. Mclaurin, J. Yip, C. M. , S. George-hyslop, P. Fraser et al., Alpha-Synuclein membrane interactions and lipid specificity, J Biol Chem, vol.275, issue.44, pp.34328-34362, 2000.

A. W. Schmid, B. Fauvet, M. Moniatte, and H. A. Lashuel, ?-Synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies, Mol. Cell. Proteomics, vol.12, pp.3543-3558, 2013.

X. Ni, R. P. Mcglinchey, J. Jiang, and J. C. Lee, Structural Insights into ?-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations, Journal of Molecular Biology, vol.431, issue.19, pp.3913-3919, 2019.

O. M. El-agnaf, S. A. Salem, K. E. Paleologou, L. J. Cooper, N. J. Fullwood et al., Alphasynuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma, Faseb J, vol.17, pp.1945-1952, 2003.

E. Angot, J. A. Steiner, C. Hansen, J. Y. Li, and P. Brundin, Are synucleinopathies prion-like disorders?, Lancet Neurology, vol.9, pp.1128-1166, 2010.

E. Angot and P. Brundin, Dissecting the potential molecular mechanisms underlying ?synuclein cell-to-cell transfer in Parkinson's disease, Parkinsonism Relat Disord, vol.15, issue.3, pp.143-147, 2009.

B. Frost and . Diamond, Prion-like mechanisms in neurodegenerative diseases, Nat Rev Neurosci, vol.11, pp.155-159, 2010.

. Cw-olanow and . Prusiner, Is Parkinson's disease a prion disorder?, Proc Natl Acad Sci, vol.106, pp.12571-12572, 2009.

M. Arotçarena and B. Dehay, Les synucléinopathies sont-elles des maladies à prions ? Pratique neurologique -FMC, vol.9, pp.145-151, 2018.

S. Mehra, S. Sahay, K. Samir, and . Maji, ?-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis, Proteins and Proteomics, vol.1867, issue.10, pp.890-908, 2019.

L. Bousset, L. Pieri, G. Ruiz-arlandis, J. Gath, and P. H. Jensen, Structural and functional characterization of two alpha-synuclein strains, Nature Communications, vol.4, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01183047

J. Gath, L. Bousset, B. Habenstein, R. Melki, A. Böckmann et al., Unlike Twins: An NMR Comparison of Two ?synuclein Polymorphs Featuring Different Toxicity, PloS One, vol.9, p.90659, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01181195

S. Ferchichi, M. Giraud, and A. Smagghe, La démence à corps de Lewy, La Revue de Gériatrie, vol.25, pp.493-498, 2000.

W. Sako, N. Murakami, Y. Izumi, and R. Kaji, The difference in putamen volume between MSA and PD: Evidence from a meta-analysis. Parkinsonism and Related Disorders, vol.20, pp.873-877, 2014.

K. A. Conway, J. D. Harper, and P. T. Lansbury, Accelerated in vitro fibril formation by a mutant ?-synuclein linked to early-onset Parkinson disease, Nat. Med, vol.4, pp.1318-1320, 1998.

J. Simon-sanchez, C. Schulte, and J. M. Bras, Genome-wide association study reveals genetic risk underlying Parkinson's disease, Nat. Genet, vol.41, pp.1308-1312, 2009.

E. K. Tan, V. R. Chandran, S. Fook-chong, H. Shen, K. Yew et al., Alphasynuclein mRNA expression in sporadic Parkinson's disease, Mov. Disord, vol.20, issue.5, pp.620-623, 2005.

M. Hashimoto, L. J. Hsu, Y. Xia, A. Takeda, A. Sisk et al., Oxidative stress induces amyloid-like aggregate formation of nacp/?-synuclein in vitro, Neuroreport, vol.10, pp.717-721, 1999.

R. J. Perrin, W. S. Woods, D. F. Clayton, and J. M. George, Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins, J. Biol. Chem, vol.276, pp.41958-41962, 2001.

R. Sharon, I. Bar-joseph, M. P. Frosch, D. M. Walsh, J. A. Hamilton et al., The formation of highly soluble oligomers of ?-synuclein is regulated by fatty acids and enhanced in Parkinson's disease, Neuron, vol.37, pp.583-595, 2003.

E. Jo, J. Mclaurin, C. M. Yip, . St, P. George-hyslop et al., ?-synuclein membrane interactions and lipid specificity, J. Biol. Chem, vol.275, pp.34328-34334, 2000.

H. A. Lashuel, D. Hartley, B. M. Petre, T. Walz, and P. T. Lansbury, Neurodegenerative disease: Amyloid pores from pathogenic mutations, Nature, vol.418, p.291, 2002.

A. L. Fink, The aggregation and fibrillation of ?-synuclein, Acc. Chem. Res, vol.39, pp.628-634, 2006.

M. J. Volles, P. T. Lansbury, and . Jr, Vesicle permeabilization by protofibrillar ?-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism, Biochemistry, vol.41, pp.4595-4602, 2002.

R. Powers, S. Lei, A. Anandhan, D. D. Marshall, B. Worley et al., Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's Disease, vol.7, p.22, 2017.

C. M. Tanner, The role of environmental toxins in the etiology of Parkinson's disease, Trends NeuroSci, vol.12, pp.49-54, 1989.

C. Song, A. Kanthasamy, H. Jin, V. Anantharam, and A. G. Kanthasamy, Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration, Neurotoxicology, vol.32, pp.586-595, 2011.

R. M. Bartlett, J. E. Holden, R. J. Nickles, D. Murali, D. L. Barbee et al., Paraquat is excluded by the blood brain barrier in rhesus macaque: An in vivo pet study, Brain Res, vol.1259, pp.74-79, 2009.

A. Montagne, S. R. Barnes, M. D. Sweeney, M. R. Halliday, A. P. Sagare et al., Blood-brain barrier breakdown in the aging human hippocampus, Neuron, vol.85, pp.296-302, 2015.

, The prevalence of Parkinson's disease: A systematic review and meta-analysis

T. Pringsheim, N. Jette, A. Frolkis, and T. D. Steeves, Movement Disorders, vol.29, issue.13, pp.1583-1590

F. Moisan, S. Kab, E. Moutengou, M. Boussac-zerebska, L. Carcaillon-bentata et al.,

F. Fréquence-de-la-maladie-de-parkinson-en, Données nationales et régionales 2010-2015, 2018.

C. A. Haaxma, B. R. Bloem, and G. F. Borm, Gender differences in Parkinson's disease, J Neurol Neurosurg Psychiatry, vol.78, pp.819-824, 2007.

S. Kab, J. Spinosi, L. Chaperon, A. Dugravot, A. Singh-manoux et al., Agricultural activities and the incidence of Parkinson's disease in the general French population, Eur J Epidemiol, vol.32, issue.3, pp.203-216, 2017.

S. Kab, F. Moisan, and A. Elbaz, Farming and incidence of motor neuron disease: French nationwide study, Eur J Neurol, vol.24, issue.9, pp.1191-1196, 2017.

D. Lajugie, N. Bertin, M. L. Chantelou, N. Vallier, A. Weill et al., Prévalence de la maladie de Parkinson et coût pour l'Assurance maladie en 2000 en France métropolitaine. Revue Médicale de l'Assurance Maladie, vol.36, pp.113-135, 2005.

P. Blin, C. Dureau-pournin, A. Foubert-samier, A. Grolleau, E. Corbillon et al.,

, Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database, Eur J Neurol, vol.22, issue.3, pp.464-71, 2015.

A. G. Fitzmaurice, S. L. Rhodes, and M. Cockburn, Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease, Neurology, vol.82, pp.419-445, 2014.

A. Elbaz and F. Moisan, The scientific bases to consider Parkinson's disease an occupational disease in agriculture professionals exposed to pesticides in France, J Epidemiol Community Health, vol.70, issue.4, pp.319-340, 2016.

M. G. Weisskopf, P. Knekt, and E. J. O'reilly, Persistent organochlorine pesticides in serum and risk of Parkinson disease, Neurology, vol.74, pp.1055-61, 2010.

A. Elbaz, C. Levecque, and J. Clavel, CYP2D6 polymorphism, pesticides exposure, and Parkinson's disease, Ann Neurol, vol.55, pp.430-434, 2004.

F. Dutheil, P. Beaune, and C. Tzourio, Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson's disease, Arch Neurol, vol.67, p.739, 2010.

I. Ahmed, P. C. Lee, and C. M. Lill, Lack of replication of the GRIN2A-by-Coffee interaction in Parkinson disease, PloS Genet, vol.10, p.1004788, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01160040

T. H. Hamza, H. Chen, and E. M. Hill-burns, Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee, PloS Genet, vol.7, p.1002237, 2011.

D. Bäckström, G. Granåsen, M. E. Domellöf, J. Linder, S. J. Mo et al., Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study, Neurology, vol.91, issue.22, pp.2045-2056, 2018.

E. N. Marieb and K. Hoehn, Anatomie et physiologie humaine, 2018.

P. Azulay, Troubles moteurs centraux (syndrome extrapyramidal, syndrome pyramidal)

F. Viallet, Chapitre 6 : Physiopathologie : organisation des ganglions de la base, Defebvre L, Verin M. La maladie de Parkinson. 3 ème édition, pp.45-54, 2015.

S. J. Lewis and R. A. Barker, Understanding the dopaminergic deficits in Parkinson's disease: Insights into disease heterogeneity, J Clin Neurosci, vol.16, issue.5, pp.620-625, 2009.

A. Nambu, Somatotopic organization of the primate basal ganglia, Front. Neuroanat, vol.5, p.26, 2011.

H. Parkinson, Les maladies de Parkinson et de Huntington sont toutes deux liées à des lésions des ganglions de la base. Mais quelles sont ces structures et à quoi servent-elles ?

M. S. Lee, J. O. Rinne, and C. D. Marsden, The pedunculopontine nucleus: its role in the genesis of movement disorders, Yonsei Med J, vol.41, pp.167-184, 2000.

C. Da-cunha, S. L. Boschen, A. Gómez, E. K. Ross, and W. S. ,

H. Gibson, K. H. Min, C. D. Lee, and . Blaha, Toward sophisticated basal ganglia neuromodulation: Review on basal ganglia deep brain stimulation, Neuroscience & Biobehavioral Reviews, vol.58, pp.186-210, 2015.

, What brain areas are affected by Parkinson's?, MEDIUM

H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. D. Tredici, Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res, vol.318, issue.1, pp.121-134, 2004.

, Noyau tubero-mammilaire

D. B. Pr-gérard-outrequin and . Boutillier, Le Cerveau, issue.3

N. Joyon and C. Duyckaerts, Chapitre 5 : Neuropathologie, Defebvre L, Verin M. La maladie de Parkinson. 3 ème édition, pp.55-68, 2015.

J. G. Choi, E. Huh, I. G. Ju, N. Kim, J. Yun et al., , vol.2, p.6, 2018.

, tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of parkinson's disease in mice, Journal of the Neurological Sciences, vol.392, pp.77-82

M. L. Lonneke and L. De, Prof Monique MB Breteler. Epidemiology of Parkinson's disease

, Lancet Neurol, vol.5, issue.6, pp.525-535, 2006.

, HAS -Service évaluation de la pertinence des soins et amélioration des pratiques et des parcours. Guide du parcours de soins -Maladie de Parkinson -Septembre, pp.978-980, 2016.

M. Fayyad, S. Salim, N. Majbour, D. Erskine, E. Stoops et al., Parkinson's disease biomarkers based on ?-synuclein. JNC, Volume150, Issue5, Special Issue: Synuclein Meeting, pp.626-636, 2019.

W. Poewe, Smelling Parkinson's Disease: New Metabolomic Biomarker for PD, ACS Cent Sci, vol.5, issue.4, pp.575-576, 2019.

A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, Accuracy of clinical diagnosis of idiopathic

, Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, vol.55, pp.181-184, 1992.

A. J. Hughes, Y. Ben-shlomo, S. E. Daniel, and A. J. Lees, What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study, Neurology, vol.42, pp.1142-1146, 1992.

C. W. Olanow, Magnetic resonance imaging in parkinsonism, Clin, vol.10, pp.405-420, 1992.

A. J. Hughes, S. E. Daniel, Y. Ben-shlomo, and A. J. Lees, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, Brain, vol.125, pp.861-870, 2002.

J. W. Langston, The Parkinson's complex: parkinsonism is just the tip of the iceberg, Ann Neurol, vol.59, pp.591-596, 2006.

G. Rizzo, M. Copetti, S. Arcuti, D. Martino, A. Fontana et al., Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis, Neurology, vol.86, pp.566-576, 2016.

J. Inserm and . Corvol, Consulté le 03/05/2019). Maladie de Parkinson

C. Moreau and L. Defebvre, Chapitre 7 : Signes moteurs

. Parkinson, 3 ème édition, pp.55-68, 2015.

Q. Bai, T. Shen, B. Xu, Q. Yu, H. Zhang et al., Quantification of the motor symptoms of Parkinson's disease, International IEEE/EMBS Conference on Neural Engineering, vol.8008297, pp.82-85, 2017.

E. Broussolle, P. Krack, S. Thobois, J. Xie-brustolin, P. Pollak et al., Contribution of Jules Froment to the study of Parkinsonian rigidity, pp.909-914, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00391547

J. Froment and H. Gardère, Parkinsonisme frustre et perte des mouvements automatiques associés, sans rigidité apparente. De la rigidité latente et des moyens de la rendre évidente, Rev Neurol, vol.I, pp.658-666, 1926.

. Inserm,

. Parkinson-study-group, DATATOP: a multicenter clinical trial in early Parkinson's disease, Arch Neurol, vol.46, pp.1052-60, 1989.

M. and A. Cenci, Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications, Front. Neurol, 2014.

P. Derkinderen and M. Vidailhet, Dyskinesia caused by L-DOPA, Rev Neurol, 2002.

J. Baufreton, T. Milekovic, Q. Li, S. Mcguire, E. M. Moraud et al., Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism, Movements Disorders, pp.1632-1642, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01797158

M. Vidailhet, A. Bonnet, and R. Marconi, Do parkinsonian symptoms and Levodopainduced dyskinesias start in the foot, Neurology, vol.44, pp.1613-1619, 1994.

W. H. Poewe, Clinical aspects of motor fluctuations in Parkinson's disease, Neurology, 1994.

J. Azulay, T. Witjas, and L. Defebvre, Chapitre 8 : Signes non moteurs

L. Defebvre and M. Vérin, La maladie de Parkinson. 3 ème Edition, pp.69-81, 2015.

N. Bódi, S. Kéri, H. Nagy, A. Moustafa, C. E. Myers et al., Reward-learning and the novelty-seeking personality: A between-and within-subjects study of the effects of dopamine agonists on young Parkinson's patients, BRAIN, vol.132, pp.2385-95, 2009.

M. Dubois, Pharmacologie des médicaments Antiparkinsoniens et des médicaments de la Maladie d'Alzheimer. Cours de 4 ème année de Pharmacie, matière Système Nerveux Central

J. Douglas and . Lanska, Chapter 33 The history of movement disorders, Handbook of Clinical Neurology, vol.95, pp.501-546, 2009.

. Inserm, Les grandes avancées -La stimulation cérébrale profonde : une petite révolution

F. Zagnoli and F. Rouhart, Maladie de Parkinson. 2 ème édition, collection Conduites, Doin, 2006.

J. Charcot, Leçons Sur Les Maladies Du Système Nerveux, pp.1872-1873

R. C. Duvoisin, Cholinergic-anticholinergic antagonism in parkinsonism, Arch Neurol, vol.17, pp.124-136, 1967.

C. , W. Olanow, M. D. Matthew, B. Stern, and M. D. Sethi, The scientific and clinical basis for the treatment of Parkinson disease, NEUROLOGY, vol.72, issue.4, pp.1-136, 2009.

A. E. Lang, Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches, Can J Neurol Sci, vol.11, pp.210-220, 1984.

J. E. Vanderheyden, D. J. Bouilliez, and . Traiter-le-parkinson, Prise en charge globale et multidisciplinaire du patient parkinsonien, 2004.

S. Thobois and E. Broussolle, Traitement initial de la maladie de Parkinson

, N° 1-C2, La Presse Médicale, vol.36, pp.86-91, 2007.

J. I. Pitt and J. D. Miller, A Concise History of Mycotoxin Research, J. Agric. Food Chem, vol.65, pp.7021-7033, 2017.

G. M. Hariz, S. Rehncrona, P. Blomstedt, P. Limousin, K. Hamberg et al., Women pioneers in basal ganglia surgery, Parkinsonism Relat Disord, vol.20, issue.2, pp.137-141, 2014.

M. Hariz, P. Blomstedt, and L. Zrinzo, Deep brain stimulation between 1947 and 1987: the untold story, Neurosurgical Focus FOC, vol.29, issue.2, p.1, 2010.

A. Benazzouz, Twenty-four years of deep brain stimulation of the subthalamic nucleus, Revue Neurologique, vol.173, issue.3, pp.103-105, 2017.

P. Limousin, P. Pollak, A. Benazzouz, D. Hoffmann, J. Bas et al., Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation, The Lancet, vol.345, pp.91-95, 1995.

A. Lozano, J. Dostrovsky, C. R. Ashby, and P. , Deep brain stimulation for Parkinson's disease: disrupting the disruption, Lancet. Neurol, vol.1, issue.4, pp.225-256, 2002.

C. Zhang, Y. Pan, L. Wang, T. Wang, J. Zhang et al., Globus pallidus internus deep brain stimulation improves axial symptoms of Parkinson patients after long-term subthalamic nucleus stimulation: A case series study, Interdisciplinary Neurosurgery. Advanced Techniques and Case Management, vol.18, p.100516, 2019.

L. Goetz, M. Bhattacharjee, M. U. Ferraye, V. Fraix, C. Maineri et al., Deep Brain Stimulation of the Pedunculopontine Nucleus Area in Parkinson Disease: MRI-Based Anatomoclinical Correlations and Optimal Target, Clinical Neurosurgery, vol.84, issue.2, pp.506-518, 2019.
URL : https://hal.archives-ouvertes.fr/cea-02186436

A. Ramirez-zamora and J. Ostrem, Globus pallidus interna or subthalamic nucleus deep brain stimulation for parkinson disease a review, JAMA Neurology, vol.75, issue.3, pp.367-372, 2018.

L. Rossi, . Foffani, . Marceglia, S. Bracchi, A. Barbieri et al., An electronic device for artefact suppression in human local field potential recordings during deep brain stimulation, Journal of Neural Engineering, vol.4, issue.2, 2007.

J. Vitek, Mechanisms of deep brain stimulation: excitation or inhibition, Mov. Disord, vol.17, issue.3, pp.69-72, 2002.

M. , E. B. Gale, and J. T. , Mechanisms of action of deep brain stimulation (DBS)

, Neuroscience and Biobehavioral Reviews, vol.32, issue.3, pp.388-407, 2008.

A. L. Benabid, S. Chabardes, J. Mitrofanis, and P. Pollak, Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease, The Lancet Neurology, vol.8, issue.1, pp.67-81, 2009.

K. Udupa and R. Chen, The mechanisms of action of deep brain stimulation and ideas for the future development, Progress in Neurobiology, vol.133, pp.27-49, 2015.

H. Michael, A. Y. Pourfar, and . Mogilner, Lead Angle Matters: Side Effects of Deep Brain Stimulation Improved with Adjustment of Lead Angle, Neuromodulation, pp.877-881, 2016.

J. I. Chalif, H. A. Sitsapesan, K. T. Pattinson, M. Herigstad, T. Z. Aziz et al., Dyspnea as a side effect of subthalamic nucleus deep brain stimulation for Parkinson's disease, Respiratory Physiology and Neurobiology, vol.192, issue.1, pp.128-133, 2014.

C. M. Matias, R. Mehanna, S. E. Cooper, A. Amit, S. F. Lempka et al., Correlation among anatomic landmarks, location of subthalamic deep brain stimulation electrodes, stimulation parameters, and side effects during programming monopolar review, Operative Neurosurgery, vol.11, issue.1, pp.99-108, 2015.

M. L. Welter, J. L. Houeto, S. Tezenas-du-montcel, V. Mesnage, A. M. Bonnet et al., Clinical predictive factors of subthalamic stimulation in Parkinson's disease, Brain, vol.125, issue.3, pp.575-583, 2002.

J. G. Nutt, S. L. Rufener, J. H. Carter, V. C. Anderson, R. Pahwa et al., Interactions between deep brain stimulation and levodopa in parkinson's disease, Neurology, vol.57, issue.10, pp.1835-1842, 2001.

, Burn DJ the effects of deep brain stimulation and levodopa on postural sway in subjects with Parkinson's disease, Neurosurgery & Psychiatry, vol.73, p.240, 2002.


D. Sante,

M. Baba, S. Nakajo, P. H. Tu, T. Tomita, K. Nakaya et al., Aggregation of ?-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am J Pathol, vol.152, pp.879-884, 1998.

A. De and M. ,

, Identification de micro-organismes par spectrométrie de masse MALDI-TOF MS

H. S. Lakshini and . Mendis, Distribution of Lipids in the Human Brain and their Differential Expression in Alzheimer's Disease: A Matrix-Assisted Laser Desorption/Ionisation-Imaging Mass Spectrometry (MALDI-IMS) Study. Doctor of Philosophy in Anatomy, 2016.

, Analyseur à temps de

G. Sighinolfi, . Mass, . Technics, . To, . Obese et al., , 2016.

C. Galvagnion and A. K. Buell, Mécanismes fondamentaux de formation de fibres amyloïdes par la protéine a-synucléine dans la maladie de Parkinson : Modélisation quantitative, Med Sci, vol.31, issue.6-7, pp.597-600, 2015.

L. Mugge, B. Krafcik, G. Pontasch, A. Alnemari, J. Neimat et al., A Review of Biomarkers Use in Parkinson with Deep Brain Stimulation: A Successful Past Promising a Bright Future, World Neurosurgery, vol.123, pp.197-207, 2019.

D. K. Trivedi, E. Sinclair, Y. Xu, D. Sarkar, C. Walton-doyle et al., Discovery of volatile biomarkers of parkinson's disease from sebum, ACS Central Science, vol.5, issue.4, pp.599-606, 2019.

A. Bougea, C. Koros, and L. Stefanis, Salivary alpha-synuclein as a biomarker for Parkinson's disease: A systematic review, Journal of Neural Transmission, 2019.

H. Zhang, L. Zhu, L. Sun, Y. Zhi, J. Ding et al., Phosphorylated ?synuclein deposits in sural nerve deriving from schwann cells: A biomarker for parkinson's disease. Parkinsonism and Related Disorders, vol.60, pp.57-63, 2019.

D. Martiny, N. Dauby, D. Konopnicki, S. Kampouridis, P. Jissendi-tchofo et al., MALDI-TOF MS contribution to the diagnosis of campylobacter rectus multiple skull base and brain abscesses, New Microbes and New Infections, vol.19, pp.83-86, 2017.

G. Wang, Z. Zhang, M. Yang, B. Xu, Q. Gao et al., Comparative proteomics analysis of human osteosarcoma by 2D DIGE with MALDI-TOF/TOF MS, Journal of Bone Oncology, vol.5, issue.4, pp.147-152, 2016.

C. L. Haddock, B. Holtz, N. Senzer, and J. Nemunaitis, Applications of HPLC-MALDI-TOF MS/MS phosphoproteomic analysis in oncological clinical diagnostics, Current. Proteomics, vol.8, issue.2, pp.153-167, 2011.

F. L. Hitti, A. G. Ramayya, B. J. Mcshane, A. I. Yang, K. A. Vaughan et al., , 2020.

, Long-term outcomes following deep brain stimulation for parkinson's disease, Journal of Neurosurgery, vol.132, issue.1, pp.205-210

C. Shahan-momjian, E. Boëx, M. I. Pralong, B. Vargas, J. Draganski et al., Aspects opératoires et péri-opératoires de la stimulation cérébrale profonde, Rev Med Suisse, vol.11, pp.972-976, 2015.